Allogene Therapeutics (ALLO) Other Operating Expenses (2023 - 2025)

Allogene Therapeutics has reported Other Operating Expenses for 4 years, with the latest figure at $2.4 million in Q2 2025.

• Quarterly Other Operating Expenses fell 52.25% year-over-year to $2.4 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 84.84% YoY) and the FY2025 annual result came in at $2.4 million, down 84.84% from the prior year.
• Other Operating Expenses declined to $2.4 million in Q2 2025 per ALLO's latest filing, from $10.7 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $13.2 million in Q4 2023 and troughed at $2.4 million in Q2 2025.
• A 3-year average of $7.8 million and a median of $7.9 million in 2024 frame the typical range for Other Operating Expenses.
• The widest YoY moves for Other Operating Expenses: up 52.25% in 2025, down 52.25% in 2025.
• Over 3 years, Other Operating Expenses stood at $13.2 million in 2023, then declined by 19.0% to $10.7 million in 2024, then plunged by 77.8% to $2.4 million in 2025.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $2.4 million, $10.7 million, and $5.0 million for Q2 2025, Q3 2024, and Q2 2024 respectively.